ERBB2 and breast carcinoma: Previously, we showed these pathways signals are downstream arms of Gi/o-GPCR signaling that stimulate HER2+ breast cancer cell growth and migration, offering resistance to HER2-targeted reagents, including trastuzumab and lapatinib [23].